TNFRSF18 and neoplasm: Combined anti-PD-1/GITR mAb treatment remarkably inhibited peritoneal ID8 tumorgrowth with 20% of mice tumor free 90 days after tumor challenge while treatmentwith either anti-PD-1 or anti-GITR mAb alone exhibited little antitumor effect.The durable antitumor effect was associated with a memory immune response andconferred by CD4+ cells and CD8+ T cells.